For the treatment of mania
Adults
Older adults
For the treatment of long-term aggression in people with Alzheimer's disease
Adults (including older adults)
Use in children and adolescents
For the treatment of behavioral disorders
The dose will depend on your child's weight:
If they weigh less than50 kilograms
If they weigh50 kilograms or more
The duration of treatment in patients with behavioral disorders should not exceed 6 weeks.
Children under 5 years should not receive treatment with Risperdal for behavioral disorders.
Patients with kidney or liver problems
Unless the disease being treated is taken into account, all initial doses and subsequent doses of risperidone should be reduced by half. Dose increases should be made more slowly in these patients.
Risperidone should be used with caution in this group of patients.
Administration form
ORAL ROUTE
Risperdal film-coated tabletswith a film coating
If you take more Risperdal than you should
It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
If you forget to take Risperdal
If you interrupt treatment with Risperdal
You should not stop taking this medication unless your doctor tells you to. Symptoms may reappear.If your doctor decides to discontinue this treatment, your dose may be gradually reduced over a few days.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Inform your doctor immediately if you experience any of the following rare side effects (which may affect up to 1 in 100 patients):
Inform your doctor immediately if you experience any of the following rare side effects (which may affect up to 1 in 1,000 patients):
You may also experience the following side effects:
Very common side effects (which may affect more than 1 in 10 people):
Common side effects (which may affect up to 1 in 10 people):
Rare side effects (which may affect up to 1 in 100 people):
Rare side effects (which may affect up to 1 in 1,000 people):
Very rare side effects (which may affect up to 1 in 10,000 people):
Frequency not known: cannot be estimated from available data
The following side effect has appeared with the use of another medicine called paliperidone, which is very similar to risperidone, so it is also expected to appear with Risperdal: Fast heart rate when standing up.
Other side effects in children and adolescents
In general, it is expected that side effects in children will be similar to those that appeared in adults.
The following side effects were reported more frequently in children and adolescents (5 to 17 years) than in adults: feeling drowsy, or less attentive, fatigue (tiredness), headache, increased appetite, vomiting, common cold symptoms, nasal congestion, abdominal pain, dizziness, cough, fever, tremor (shaking), diarrhoea and urinary incontinence.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet.You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
Do not store above30°C.
Blister packs:Store in the original packaging to protect it from light.
Medications should not be disposed of through drains or trash. Dispose of packaging and medications you no longer need at theSIGREcollection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
The active ingredient is risperidone
Each film-coated tablet of Risperdal contains 1, 3 or 6 milligrams of risperidone.
The other components are:
Risperdal 1 mg film-coated tablets:
Core of the tablet:Lactose monohydrate, Cornstarch, Microcrystalline cellulose (E460), Hypromellose (E464), Magnesium stearate, Colloidal anhydrous silica, Sodium lauryl sulfate.
Coating:Hypromellose (E464), Propylene glycol (E490).
Risperdal 3 mg film-coated tablets:
Core of the tablet:Lactose monohydrate, Cornstarch, Microcrystalline cellulose (E460), Hypromellose (E464), Magnesium stearate, Colloidal anhydrous silica, Sodium lauryl sulfate.
Coating:Hypromellose (E464), Propylene glycol (E490), Titanium dioxide (E171), Talc (E553B), Quinoline yellow (E104).
Risperdal 6 mg film-coated tablets:
Core of the tablet:Lactose monohydrate, Cornstarch, Microcrystalline cellulose (E460), Magnesium stearate, Colloidal anhydrous silica, Sodium lauryl sulfate.
Coating:Hypromellose (E464), Propylene glycol (E490), Titanium dioxide (E171), Talc (E553B), Quinoline yellow (E104), Sunset yellow FCF (E110).
Appearance of Risperdal and packaging contents
Risperdal film-coated tablets are packaged in PVC/LDPE/PVDC/aluminum blisters and HDPE bottles with a child-resistant plastic cap.
Film-coated tablets
The film-coated tablets are engraved with "RIS 1", "RIS 3" and "RIS 6" respectively on one side, and may also be engraved with "JANSSEN" on the other side.
Package sizes
Risperdal film-coated tablets are available in the following package sizes:
Only some package sizes may be marketed.
Marketing authorization holder
JANSSEN-CILAG, S.A.
Paseo de Las Doce Estrellas, 5-7
28042 Madrid, Spain
+34 917228100
+34 917228101
Responsible for batch release
Janssen Cilag S.P.A.
Via C. Janssen (Borgo San Michelle, Latina) - I 04100 – Italy
This medicinal product is authorized in the member states of the European Economic Area and in the United Kingdom (Northern Ireland)with the following names:
Austria:Risperdal
Belgium: RISPERDAL
Cyprus:RISPERDAL
Czech Republic:RISPERDAL
Denmark: RISPERDAL
Estonia:RISPOLEPT
Finland:RISPERDAL
France:RISPERDAL
Germany:RISPERDAL1mg; 2mg; 3mg; 4mg/ Risperdal 0.5mg; 6mg / Risperdal Lösung 1mg/ml
Greece:RISPERDAL
Hungary:RISPERDAL
Iceland:RISPERDAL
Ireland:RISPERDAL
Italy:RISPERDAL
Lithuania:RISPOLEPT
Latvia:RISPOLEPT
Luxembourg:RISPERDAL
Malta:RISPERDAL
Netherlands:RISPERDAL
Norway:RISPERDAL
Poland:RISPOLEPT
Portugal:RISPERDAL
Romania:RISPOLEPT
Slovenia:RISPERDAL
Spain:RISPERDAL
Sweden:RISPERDAL
United Kingdom (Northern Ireland):RISPERDAL
Last revision date of this leaflet:August 2022.
For detailed and updated information on this medicinal product, please consult the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) (http://www.aemps.gob.es).
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.